Learn how Tumor Organoids Provide a Unique In Vitro Clinical Trial Platform
Early stage oncology drug discovery including drug screening needs improved on two fronts. Firstly, more advanced in vitro models are needed to better recapitulate the complexity and heterogeneity of the clinical cancer population. Secondly, the current inefficient and costly linear drug discovery workflow needs to be overhauled, to move to a more efficient, matrixed process.
This White Paper details how patient-derived tumor organoids are revolutionizing drug discovery. This new system provides more translational and predictive data, and models which are amenable to concurrent lead compound and target population identification through a matrixed, high-throughput screening (HTS) approach.
Download This White Paper to Understand:
- The key benefits of patient-derived tumor organoids, including high clinical relevance through the preservation of parental tumor genomic and epigenomic features
- How tumor organoids provide a “clinical trial in a dish”, allowing matrix HTS to accelerate lead compound progression combined with target population identification
- The main components required for a successful organoid-based drug discovery platform